Clinical characteristics, molecular markers and Aurora B staining
| Patient | Age (years), sex | Survival (months) | Treatment | p53 IHC (%) | EGFR FISH | Ki-67 (%) | Aurora B IHC |
|---|---|---|---|---|---|---|---|
| A, amplified and overexpressed; Bx, biopsy; C, chemotherapy regimen; EGFR, epidermal growth factor receptor; F, female; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; Ki-67%: Ki-67 is a marker of cell proliferation in paraffin-embedded tissues, with % of tumor cells that are stained by antibody to Ki-67; LTS, long-term survivor; M, male; NA, not amplified or overexpressed; ND, not determined; OR, gross total (100%) or near total (>95%) resection; p53 IHC %, the percentage of tumour cells that are stained by antibody to Tp53; STS, short-term survivor; survival >, patient still alive; XRT, therapeutic radiotherapy; × followed by a number represents the number of radiotherapy or separate chemotherapy regimens administered or intended for treatment; −, no cells; 1+, <25% scattered cells; 2+, 25–50% of tumour cells; 3+, >50% cells, with heavy, diffuse staining. | |||||||
| STS v LTS (one-sided Student’s t test): *p<0.001 for survival. | |||||||
| †, age comparison, p = 0.34. | |||||||
| ‡, Ki-67 staining comparison, p = 0.76. | |||||||
| STS1 | 64, F | 9.0 | OR, XRT, C | ND | NA | 18 | 1+ |
| STS2 | 56, M | 8.7 | OR, XRT, C×2 | ND | NA | N/D | 3+ |
| STS3 | 46, F | 8.4 | OR, XRT, C×2 | <10 | NA | 12 | 1+ |
| STS4 | 22, M | 8.7 | OR, XRT, C×3 | 75–100 | NA | 14 | – |
| STS5 | 63, M | 3.8 | OR, XRT, C | 0 | A | 16 | 1+ |
| STS6 | 64, M | 4.1 | OR, XRT, C | <10 | NA | 4 | – |
| STS7 | 59, F | 3.6 | OR, XRT | <10 | NA | 13 | 2+ |
| STS8 | 54, F | 7.7 | OR, XRT, C×2 | 75–100 | NA | 30 | 3+ |
| STS9 | 46, M | 6.1 | OR, XRT, C×2 | <10 | NA | 4 | – |
| STS10 | 48, F | 8.5 | OR, XRT, C, Bx, C | 1–2 | NA | 17.5 | 2+ |
| STS11 | 49, M | 7.1 | OR, XRT×2, C×2 | 100 | NA | 14 | 3+ |
| STS12 | 58, M | 5.1 | OR, XRT, C | 75–100 | NA | 6.5 | 3+ |
| Mean (SD) | 52.4 (11.7)† | 6.8 (2.1)* | 12.6 (8.1)‡ | ||||
| LTS1 | 58, M | 26 | OR, XRT, C×2 | 75–100 | A | 14.5 | – |
| LTS2 | 54, F | >24 | OR, XRT, C | <10 | A | 11.5 | Trace |
| LTS3 | 29, M | 29 | OR, XRT, C×2 | 75–100 | NA | 50 | – |
| LTS4 | 39, M | >24 | OR, XRT, C×2 | 25–50 | NA | 30 | Trace |
| LTS5 | 59, M | 27 | OR, XRT, C | <10 | A | 5 | – |
| LTS6 | 40, M | 37 | OR, XRT, C×2 | <25 | A | 12.5 | – |
| LTS7 | 50, M | >24 | OR, XRT, C | <10 | NA | 1.5 | – |
| LTS8 | 62, M | >26 | OR, XRT, C×2 | 75–100 | NA | 20 | – |
| LTS9 | 49, M | >24 | OR, XRT, C×2 | 75–100 | A | 15.5 | 3+ |
| LTS10 | 48, M | >32 | OR, XRT, C | 75–100 | A | 12 | – |
| LTS11 | 56, F | >26 | OR, XRT, C | <10 | NA | 9.5 | – |
| LTS12 | 51, M | >34 | OR, XRT, C×3 | <10 | A | 5 | – |
| LTS13 | 64, F | >27 | OR, XRT, C | <10 | NA | 15 | – |
| #Mean (SD) | 50.7 (10)† | >27.7 (4)* | 15.5 (12.6)‡ | ||||